OFS
VRTX icon

Orrstown Financial Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Orrstown Financial Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,137
Closed -$506K – 142
2025
Q2 		$506K Buy
1,137
+160
+16% +$73.7K 0.11% 93
2025
Q1 		$474K Buy
977
+30
+3% +$14K 0.11% 91
2024
Q4 		$381K Buy
947
+248
+35% +$115K 0.1% 103
2024
Q3 		$325K Buy
699
+95
+16% +$45.6K 0.1% 110
2024
Q2 		$283K Buy
604
+88
+17% +$38.2K 0.15% 71
2024
Q1 		$216K Buy
+516
New +$218K 0.12% 79

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Orrstown Financial Services's VRTX Position: Q3 2025 in Review

Orrstown Financial Services sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 1,137 shares — an estimated $506K sold.

Orrstown Financial Services first reported a position in VRTX in Q1 2024 and held it in 6 quarters. The position peaked at $506K in Q2 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Orrstown Financial Services reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Orrstown Financial Services sold 1,137 Vertex Pharmaceuticals shares in Q3 2025, an estimated $506K.
  • Orrstown Financial Services first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • Orrstown Financial Services's Vertex Pharmaceuticals position peaked at $506K in Q2 2025.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Orrstown Financial Services's 13F filing for Q3 2025, filed 10 Oct 2025.